Adiposity · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
Cholesterol mg/dL · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
Serum fasting triglyceride (TG, mmol/L) · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
Serum low‐density lipoprotein (LDL, mmol/L) · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
CHD events · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in coronary heart disease events compared with lower PUFA (moderate certainty).
1 finding from 1 review
Stroke · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in stroke compared with lower PUFA (low certainty).
1 finding from 1 review
Major adverse cardiac and cerebrovascular events · people with or without existing CVD, men and women
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes major adverse cardiac and cerebrovascular events compared with lower PUFA (very low certainty).
1 finding from 1 review
Cardiovascular mortality · people with or without existing cardiovascular disease, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in cardiovascular mortality compared with lower PUFA (low certainty).
1 finding from 1 review
Cardiovascular events · people with or without existing cardiovascular disease, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in cardiovascular events compared with lower PUFA (moderate certainty).
1 finding from 1 review
Coronary heart disease mortality – CHD deaths · people with or without existing cardiovascular disease, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in coronary heart disease mortality compared with lower PUFA (low certainty).
1 finding from 1 review
Atrial fibrillation and arrhythmias · people with or without existing cardiovascular disease, men and women
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes atrial fibrillation and arrhythmias compared with lower PUFA (very low certainty).
1 finding from 1 review
Weight (kg) · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
Myocardial infarction · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (high dose) showed no clear difference in myocardial infarction compared with homocysteine‐lowering interventions (low dose) (moderate certainty).
1 finding from 1 review
Stroke · people with or without existing cardiovascular disease, men and women
It is very uncertain whether homocysteine‐lowering interventions (high dose) changes stroke compared with homocysteine‐lowering interventions (low dose) (very low certainty).
1 finding from 1 review
Death by any cause · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (high dose) showed no clear difference in death by any cause compared with homocysteine‐lowering interventions (low dose) (moderate certainty).
1 finding from 1 review
Cancer · people with or without existing cardiovascular disease, men and women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants' quality of life Measured by EQ‐5D and KCCQ. Higher scores indicate high‐quality of life. · people with heart failure with or without their surrogate decision‐makers/carers
1 finding from 1 review
Participants' depression Measured on PHQ‐8, PHQ‐9, and HADS. Higher scores indicate high depression · people with heart failure with or without their surrogate decision‐makers/carers
1 finding from 1 review
Quality of communication Measured on Quality of Patient‐Clinician Communication About End‐of‐Life Care. Higher score indicates high satisfaction with the quality of communication Assessed after intervention · people with heart failure with or without their surrogate decision‐makers/carers
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Intervention not reported
RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review